CliffBio

Genzyme

Patent cliffs & loss of exclusivity

Genzyme was a biotechnology company developing diagnostic enzyme products with applications in the diagnostic process of various chronic diseases. The company was acquired by Sanofi in 2011, and rebranded as Senofi Genzyme.

Company

Also Known AsSenofi Genzyme
AngelList URLhttps://angel.co/genzyme-2
Legal NameGenzyme Limited
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/genzyme
Legal Entity Identifier549300ZNNO34O8GXUE47
Pitchbook URLhttps://pitchbook.com/profiles/company/149725-72#overview
Stock SymbolGENZ

8 upcoming patent cliffs

DrugIngredientTypeCliff
  1. CAPRELSAVANDETANIBSmall mol.Aug 2028
  2. CAPRELSAVANDETANIBSmall mol.Aug 2028
  3. RENVELASEVELAMER CARBONATESmall mol.Dec 2030
  4. RENVELASEVELAMER CARBONATESmall mol.Dec 2030
  5. QFITLIAFITUSIRAN SODIUMSmall mol.Dec 2036
  6. QFITLIAFITUSIRAN SODIUMSmall mol.Dec 2036
  7. CERDELGAELIGLUSTAT TARTRATESmall mol.Dec 2038
  8. WAYRILZRILZABRUTINIBSmall mol.Feb 2041
  9. RENAGELSEVELAMER HYDROCHLORIDESmall mol.—
  10. FLUDARAFLUDARABINE PHOSPHATESmall mol.—
  11. CLOLARCLOFARABINESmall mol.—
  12. MOZOBILPLERIXAFORSmall mol.—
  13. RENAGELSEVELAMER HYDROCHLORIDESmall mol.—
  14. RENAGELSEVELAMER HYDROCHLORIDESmall mol.—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.